There is great unmet need for better treatment and diagnosis of renal cancer (RCC), the most lethal of all urological malignancies. No method is available to predict RCC response to targeted therapy, nor to accurately identify high-risk patients for entry into adjuvant trials. Indeed, a majority of patients with disseminated RCC do not benefit from treatment but may suffer serious side effects, costing ≈£70M p.a. across UK.
We have developed a protein biomarker-based algorithm to risk stratify overall survival and response to a front-line treatment (sunitinib) in metastatic RCC, accounting for current clinical variables. Biomarker discovery has been difficult in RCC, and no marker or combination has shown the strong separation of patient groups achieved by our approach. This proposal is for gold-standard validation and benchmarking, building links with Vanderbilt University (USA) and to explore prognostication in localised disease with novel and previously identified markers, energised by material from SCOTRRCC.